BACKGROUND: The second-generation cryoballoon (CB-A) (Arctic Front Advance, Cryocath, Medtronic, MN, USA) might significantly improve procedural outcome with respect to the first-generation balloon. These technological improvements might also question the current recommendation of the need a 4-min freeze to achieve durable pulmonary vein isolation (PVI). OBJECTIVE: The main aim of the study was to analyze the procedural efficacy of a 3-min freeze-thaw cycles with the CB-A balloon in the terms of rates of acute PVI and 6-month outcome. METHODS: Patients having undergone CB-A for PAF or early persistent AF, with 3-min freeze-thaw cycles were consecutively included in our analysis. Acute procedural success was measured in terms of the rate of PVI. Short-term follow-up was evaluated by the means of 24-h Holters and clinical examinations at regular intervals. RESULTS: Fifty-two consecutive patients (35 male (67 %); mean age, 59.8 ± 10.5) were included. Mean procedure and fluoroscopy times were 96 ± 15 and 13.2 ± 8.3 min, respectively. Mean time from groin puncture to catheter extraction was 60.4 ± 20 min. After a mean of 1.5 freeze cycles per vein of 3 min in duration, all 208 (100 %) PVs could be isolated with the CB-A. A total 192 (91 %) veins were isolated during the first freeze. At a mean of 5.7-month follow-up, 82 % of patients were free of AF. CONCLUSION: CB-A is effective in producing PVI by using 3-min-duration freeze cycles. After a mean of 1.5 freeze per vein, freedom from AF was achieved in 82 % of patients at 6-month follow-up.
BACKGROUND: The second-generation cryoballoon (CB-A) (Arctic Front Advance, Cryocath, Medtronic, MN, USA) might significantly improve procedural outcome with respect to the first-generation balloon. These technological improvements might also question the current recommendation of the need a 4-min freeze to achieve durable pulmonary vein isolation (PVI). OBJECTIVE: The main aim of the study was to analyze the procedural efficacy of a 3-min freeze-thaw cycles with the CB-A balloon in the terms of rates of acute PVI and 6-month outcome. METHODS:Patients having undergone CB-A for PAF or early persistent AF, with 3-min freeze-thaw cycles were consecutively included in our analysis. Acute procedural success was measured in terms of the rate of PVI. Short-term follow-up was evaluated by the means of 24-h Holters and clinical examinations at regular intervals. RESULTS: Fifty-two consecutive patients (35 male (67 %); mean age, 59.8 ± 10.5) were included. Mean procedure and fluoroscopy times were 96 ± 15 and 13.2 ± 8.3 min, respectively. Mean time from groin puncture to catheter extraction was 60.4 ± 20 min. After a mean of 1.5 freeze cycles per vein of 3 min in duration, all 208 (100 %) PVs could be isolated with the CB-A. A total 192 (91 %) veins were isolated during the first freeze. At a mean of 5.7-month follow-up, 82 % of patients were free of AF. CONCLUSION:CB-A is effective in producing PVI by using 3-min-duration freeze cycles. After a mean of 1.5 freeze per vein, freedom from AF was achieved in 82 % of patients at 6-month follow-up.
Authors: Thomas Neumann; Maciej Wójcik; Alexander Berkowitsch; Damir Erkapic; Sergey Zaltsberg; Harald Greiss; Dimitri Pajitnev; Stefan Lehinant; Jörn Schmitt; Christian W Hamm; Heinz F Pitschner; Malte Kuniss Journal: Europace Date: 2013-02-17 Impact factor: 5.214
Authors: Andreas Metzner; Andre Burchard; Peter Wohlmuth; Peter Rausch; Alexander Bardyszewski; Christina Gienapp; Roland Richard Tilz; Andreas Rillig; Shibu Mathew; Sebastian Deiss; Hisaki Makimoto; Feifan Ouyang; Karl-Heinz Kuck; Erik Wissner Journal: Circ Arrhythm Electrophysiol Date: 2013-06-07
Authors: Michael Kühne; Sven Knecht; David Altmann; Nadine Kawel; Peter Ammann; Beat Schaer; Stefan Osswald; Christian Sticherling Journal: J Interv Card Electrophysiol Date: 2012-10-23 Impact factor: 1.900
Authors: Gunnar Klein; Hanno Oswald; Ajmal Gardiwal; Ulrich Lüsebrink; Christoph Lissel; Hong Yu; Helmut Drexler Journal: Heart Rhythm Date: 2008-02-16 Impact factor: 6.343
Authors: Gian Battista Chierchia; Carlo de Asmundis; Stephan-Andreas Müller-Burri; Andrea Sarkozy; Lucio Capulzini; Gaetano Paparella; Sergio Chierchia; Markus Roos; Pedro Brugada Journal: Europace Date: 2008-12-22 Impact factor: 5.214
Authors: Alexander Fürnkranz; Stefano Bordignon; Boris Schmidt; Melanie Gunawardene; Britta Schulte-Hahn; Verena Urban; Frank Bode; Bernd Nowak; Julian K R Chun Journal: J Cardiovasc Electrophysiol Date: 2013-02-11
Authors: Thomas Neumann; Jürgen Vogt; Burghard Schumacher; Anja Dorszewski; Malte Kuniss; Hans Neuser; Klaus Kurzidim; Alexander Berkowitsch; Marcus Koller; Johannes Heintze; Ursula Scholz; Ulrike Wetzel; Michael A E Schneider; Dieter Horstkotte; Christian W Hamm; Heinz-Friedrich Pitschner Journal: J Am Coll Cardiol Date: 2008-07-22 Impact factor: 24.094
Authors: Jayakeerthi Yoganarasimha Rao; Gian-Battista Chierchia; Carlo de Asmundis; Ruben Casado-Arroyo; Ingrid Overeinder; Andrea Sarkozy; Gaetano Paparella; Lucio Capulzini; Antonio Sorgente; Moises Rodriguez-Manero; Danilo Ricciardi; Mehdi Namdar; Pedro Brugada Journal: J Cardiovasc Med (Hagerstown) Date: 2014-03 Impact factor: 2.160
Authors: Jesus M Paylos; Aracelis Morales; Luis Azcona; Marisol Paradela; Raquel Yagüe; Fernando Gómez-Guijarro; Lourdes Lacal; R N Clara Ferrero; Octavio Rodríguez Journal: J Atr Fibrillation Date: 2016-04-30
Authors: A Ambrogelly; S Kamtekar; A Sauerwald; B Ruan; D Tumbula-Hansen; D Kennedy; I Ahel; D Söll Journal: Cell Mol Life Sci Date: 2004-10 Impact factor: 9.261